Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas

被引:302
作者
Koebel, Martin [1 ,2 ]
Kalloger, Steve E. [3 ]
Huntsman, David G. [3 ]
Santos, Jennifer L. [4 ]
Swenerton, Kenneth D. [4 ]
Seidman, Jeffrey D. [5 ,6 ]
Gilks, C. Blake [3 ]
机构
[1] Univ Calgary, Dept Pathol, Calgary, AB T2N 2T9, Canada
[2] Univ Calgary, Dept Lab Med, Calgary, AB T2N 2T9, Canada
[3] British Columbia Canc Agcy, Vancouver Gen Hosp, Dept Pathol, Genet Pathol Evaluat Ctr,Prostate Res Ctr, Vancouver, BC V5Z 4E6, Canada
[4] British Columbia Canc Agcy, Cheryl Brown Ovarian Canc Outcomes Unit, Vancouver, BC V5Z 4E6, Canada
[5] Washington Hosp Ctr, Dept Pathol, Washington, DC 20010 USA
[6] Washington Hosp Ctr, Dept Lab Med, Washington, DC 20010 USA
关键词
Ovary; Cancer; Ovarian carcinoma; Stage; Type; GRADE SEROUS CARCINOMA; CLEAR-CELL; UNDIFFERENTIATED CARCINOMA; PROGNOSTIC-SIGNIFICANCE; ENDOMETRIOID CARCINOMA; HISTOLOGIC-TYPE; FALLOPIAN-TUBE; 2-TIER SYSTEM; NEW-MODEL; CANCER;
D O I
10.1097/PGP.0b013e3181c042b6
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Although there are recognized differences in the type of ovarian carcinomas between those tumors diagnosed at low versus high stage, there is a lack of data on stage distribution of ovarian carcinomas diagnosed according to the current histopathologic criteria from large population-based cohorts. We reviewed full slide sets of 1009 cases of 2555 patients diagnosed with ovarian carcinoma that were referred to the British Columbia Cancer Agency over a 16-year period (1984 to 2000). On the basis of the reviewed cases we extrapolated the distribution of tumor type in low-stage (I/II) and high-stage (III/IV) tumors. We then compared the frequencies with those seen in a large hospital practice. The overall frequency of tumor types was as follows: high-grade serous-68.1%, clear-cell-12.2%, endometrioid-11.3%, mucinous-3.4%, low-grade serous-3.4%, rare types-1.6%. High-grade serous carcinomas accounted for 35.5% of stage I/II tumors and 87.7% of stage III/IV tumors. In contrast, clear-cell (26.2% vs. 4.5%), endometrioid (26.6% vs. 2.5%), and mucinous (7.5% vs. 1.2%) carcinomas were relatively more common among the low-stage versus high-stage tumors. This distribution was found to be very similar in 410 consecutive cases from the Washington Hospital Center. The distribution of ovarian carcinoma types differs significantly in patients with low-stage versus high-stage ovarian carcinoma when contemporary diagnostic criteria are used, with consistent results seen in 2 independent case series. These findings reflect important biological differences in the behavior of the major tumor types, with important clinical implications.
引用
收藏
页码:203 / 211
页数:9
相关论文
共 41 条
[1]  
ABELL MR, 1966, CAN MED ASSOC J, V94, P1102
[2]  
AURE JC, 1971, OBSTET GYNECOL, V37, P1
[3]   Is randomized trial of neoadjuvant chemotherapy of ovarian cancer necessary? [J].
Bose, Chinmoy K. .
GYNECOLOGIC ONCOLOGY, 2009, 114 (02) :371-371
[4]   The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection [J].
Brown, Patrick O. ;
Palmer, Chana .
PLOS MEDICINE, 2009, 6 (07)
[5]   The distal fallopian tube: a new model for pelvic serous carcinogenesis [J].
Crum, Christopher P. ;
Drapkin, Ronny ;
Miron, Alexander ;
Ince, Tan A. ;
Muto, Michael ;
Kindelberger, David W. ;
Lee, Yonghee .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (01) :3-9
[6]   HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma [J].
Davidson, B ;
Elstrand, MB ;
McMaster, MT ;
Berner, A ;
Kurman, RJ ;
Risberg, B ;
Trope, CG ;
Shih, IM .
GYNECOLOGIC ONCOLOGY, 2005, 96 (01) :42-47
[7]   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
[8]   Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis [J].
Faggad, Areeg ;
Darb-Esfahani, Silvia ;
Wirtz, Ralph ;
Sinn, Bruno ;
Sehouli, Jalid ;
Koensgen, Dominique ;
Lage, Hermann ;
Weichert, Wilko ;
Noske, Aurelia ;
Budczies, Jan ;
Mueller, Berit M. ;
Buckendahl, Ann-Christin ;
Roeske, Annika ;
Elwali, Nasr Eldin ;
Dietel, Manfred ;
Denkert, Carsten .
MODERN PATHOLOGY, 2009, 22 (04) :579-588
[9]   Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma [J].
Gilks, C. Blake ;
Ionescu, Diana N. ;
Kalloger, Steve E. ;
Koebel, Martin ;
Irving, Julie ;
Clarke, Blaise ;
Santos, Jennifer ;
Le, Nhu ;
Moravan, Veronika ;
Swenerton, Kenneth .
HUMAN PATHOLOGY, 2008, 39 (08) :1239-1251
[10]   Ovarian carcinoma pathology and genetics: recent advances [J].
Gilks, C. Blake ;
Prat, Jaime .
HUMAN PATHOLOGY, 2009, 40 (09) :1213-1223